Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus $^{18}$F-F-FDG in Oncology: A Systematic Review

Giorgio Treglia 1,2,3,4,5,*, Barbara Muoio 6,†, Hessamoddin Roustaei 7, Zahra Kiamanesh 7, Kamran Aryana 7 and Ramin Sadeghi 7

Citation: Treglia, G.; Muoio, B.; Roustaei, H.; Kiamanesh, Z.; Aryana, K.; Sadeghi, R. Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus $^{18}$F-F-FDG in Oncology: A Systematic Review. Int. J. Mol. Sci. 2021, 22, 11192. https://doi.org/10.3390/ijms222011192

Abstract: Several recent studies comparing radiolabeled fibroblast activation protein inhibitors (FAPI) and fluorine-18 fluorodeoxyglucose ($^{18}$F-F-FDG) as positron emission tomography (PET) radiotracers in oncology have been published. The aim of this systematic review is to perform an updated evidence-based summary about the comparison of these PET radiotracers in oncology to better address further research in this setting. Studies or subsets of studies comparing radiolabeled FAPI and $^{18}$F-F-FDG as PET radiotracers in oncology were eligible for inclusion in this systematic review. A systematic literature search of PubMed/MEDLINE and Cochrane library databases was performed until August 2021. Literature data about the comparison of $^{18}$F-F-FDG and radiolabeled FAPI are rapidly increasing. Overall, taking into account radiotracer uptake and tumor-to-background uptake ratio, compared to $^{18}$F-F-FDG PET, an equal or higher detection of primary tumors and/or metastatic lesions was usually demonstrated by using radiolabeled FAPI PET. In particular, the cancer entities with better detection rate of tumor lesions by using radiolabeled FAPI PET, compared to $^{18}$F-F-FDG PET, were gastrointestinal tumors, liver tumors, breast cancer and nasopharyngeal carcinoma. Further comparison studies are needed to better evaluate the best field of application of radiolabeled FAPI PET.

Keywords: PET; positron emission tomography; FAPI; fibroblast activation protein; fluorodeoxyglucose; FDG; oncology; cancer; imaging; systematic review

1. Introduction

Positron emission tomography (PET) is a functional imaging technique extensively used in oncology to diagnose tumors early, even in the absence of morphological abnormalities. Hybrid imaging modalities, including PET/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI), are currently available and may allow to combine functional and morphological information on cancer patients. Different PET radiotracers evaluating different metabolic pathways or receptor statuses may be used
in this setting [1–4]. Although many PET radiotracers are currently available, fluorine-18 fluorodeoxyglucose ([18F]F-FDG) is still the most widely used PET radiotracer in oncology [2–4]. [18F]F-FDG uptake is related to glucose metabolism, and increased glucose metabolism is one of the hallmarks of many cancer types. However, [18F]F-FDG has known limitations, such as its high physiological uptake in many normal tissues (hampering the detection of tumor lesions in these sites), its low uptake in certain tumor types (as several well-differentiated tumors), and a lack of specificity (as several diseases may be characterized by increasing glucose metabolism); these limitations represent the basis for the continuous development of new PET radiotracers in oncology [2–4].

Recently, fibroblast activation protein (FAP) expression in cancer-associated fibroblasts (CAFs) was evaluated as a possible target for PET imaging in oncology [5,6]. CAFs are the main component of tumor microenvironment, which has a pivotal role in cancer development, including tumor growth, tumor invasion and metastatic spread [7]. FAP is a transmembrane glycoprotein enzyme, which is overexpressed on the cell surface of activated CAFs of multiple tumor types and, in particular, in many epithelial carcinomas (especially in those characterized by a strong desmoplastic reaction, as they can comprise up to 90% of the tumor mass). Conversely, there is a low expression of FAP in ubiquitous resting fibroblasts of healthy tissues [7]. However, FAP expression is not cancer specific but activated fibroblasts in nonmalignant diseases may overexpress FAP [7,8].

Several radiolabeled FAP inhibitors (FAPI) targeting FAP expression in CAFs and characterized by rapid renal clearance and high tumor-to-background uptake ratio (TBR) have been developed to allow early cancer detection through PET imaging [9]. Several recent studies comparing radiolabeled FAPI and [18F]F-FDG as PET radiotracers in oncology have been published. The aim of this systematic review is to perform an updated evidence-based summary about the comparison of these PET radiotracers in oncology to better address further research in this setting.

2. Results

2.1. Literature Search

The review question was the diagnostic comparison of radiolabeled FAPI and [18F]F-FDG as PET radiotracers in oncology. The literature search results using a systematic approach are reported in Figure 1. The comprehensive computer literature search from PubMed/MEDLINE and Cochrane library database revealed 162 records. Reviewing titles and abstracts, 136 records were excluded: 55 because they were not in the field of interest of this review; 12 reviews, editorials, letters or comments; and 69 case reports or small case series (<8 patients). Twenty-six articles were selected and retrieved in full-text version. No additional studies were found screening the references of the selected articles. Finally, 26 articles (925 patients) including data on the comparison between radiolabeled FAPI and [18F]F-FDG as PET radiotracers in oncology were included in the systematic review [10–35]. The characteristics of the studies selected for the systematic review are presented in Table 1, Table 2, Table 3. The overall quality assessment of the studies is reported in Figure 2.
**Research question:** Head-to-head comparison of radiolabeled FAPI and [18F]FDG as PET radiotracers in oncology

**Database screened:** PubMed/MEDLINE and Cochrane library (until 28 August 2021)

---

**Figure 1.** Scheme of article selection for the systematic review.
| Authors          | Year | Type of Study | Country          | Cancer Evaluated                               | PET Radiopharmaceuticals                                      | No. of Cases Compared | Age (Years) | Male% |
|------------------|------|---------------|------------------|------------------------------------------------|-------------------------------------------------------------|----------------------|-------------|-------|
| Ballal et al.    | 2021 | P-Mo          | India            | Various cancers                                | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-SA.FAPI   | 54                   | 48.4        | 37%   |
| Chen et al.      | 2020 | P-Mo          | China            | Various cancers                                | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 75                   | 61.5        | 63%   |
| Chen et al.      | 2021 | P-Mo          | China            | Various cancers                                | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 68                   | 57.0        | 59%   |
| Dendl et al.     | 2021 | R-Bi          | Germany and South Africa | Gynecological cancers | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI tracers (FAPI-02, FAPI-04 or FAPI-46) | 10                   | 59.5        | 0%    |
| Elboga et al.    | 2021 | R-Mo          | Turkey           | Breast cancer                                  | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 48                   | 53.3        | 0%    |
| Giesel et al.    | 2021 | R-Mo          | Germany, USA and South Africa | Various cancers | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI tracers (FAPI-02, FAPI-04, FAPI-46 or FAPI-74) | 71                   | 60.0        | 61%   |
| Gao et al.       | 2021 | R-Mo          | China            | Liver cancer                                   | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 34                   | 60.6        | 74%   |
| Jiang et al.     | 2021 | R-Bi          | China            | Gastric cancer                                 | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 38                   | 67.5        | 76%   |
| Kömek et al.     | 2021 | P-Mo          | Turkey           | Breast cancer                                  | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 20                   | 64.0        | 51%   |
| Kreppel et al.   | 2021 | R-Mo          | Germany          | Liver metastases of NEt\(\_{S}\)              | \(^{[18]}\)F-FDG, \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04 and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-TOC | 13                   | 66.8        | 62%   |
| Kuten et al.     | 2021 | P-Mo          | Israel           | Gastric cancer                                 | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 13                   | 70.0        | 46%   |
| Lan et al.       | 2021 | P-Mo          | China            | Various cancers                                | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 123                  | 56.1        | 56%   |
| Linz et al.      | 2021 | P-Mo          | Germany          | Oral cancer                                    | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 10                   | 58.0        | 80%   |
| Pang et al.      | 2021 | R-Mo          | China            | Gastrointestinal cancers                       | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 35                   | 64.0        | 72%   |
| Qin et al.       | 2021 | P-Mo          | China            | Gastric cancer                                 | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 20                   | 56.0        | 45%   |
| Qin et al.       | 2021 | P-Mo          | China            | Nasopharyngeal cancer                          | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 15                   | 51.2        | 53%   |
| Qin et al.       | 2021 | R-Mo          | China            | Bone metastases or bone and joint lesions      | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 29                   | 56.6        | 57%   |
| Sahin et al.     | 2021 | R-Mo          | Turkey           | Liver metastases of gastrointestinal cancers   | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 31                   | 61.9        | 61%   |
| Serfling et al.  | 2021 | R-Mo          | Germany          | Suspicious tonsillar tumor or CUP              | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 8                    | 62.0        | 75%   |
| Shi et al.       | 2021 | P-Mo          | China            | Liver cancer                                   | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 20                   | 58.0        | 90%   |
| Wang et al.      | 2021 | P-Mo          | China            | Various cancers                                | \(^{[18]}\)F-FDG and AI \(^{[18]}\)F-FDG-NOTA-FAPI          | 10                   | 63.6        | 40%   |
| Wang et al.      | 2021 | R-Mo          | China            | Liver cancer                                   | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 25                   | 59.4        | 96%   |
| Zhao et al.      | 2021 | R-Mo          | China            | Esophageal cancer                              | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 20                   | 60.0        | 86%   |
| Zhao et al.      | 2021 | R-Mo          | China            | Peritoneal carcinomatosis                      | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 46                   | 57.0        | 30%   |
| Zhao et al.      | 2021 | R-Mo          | China            | Nasopharyngeal cancer                          | \(^{[18]}\)F-FDG and \(^{[68]}\)Ga\(_{56}\)Ga-DOTA-FAPI-04   | 45                   | 50.0        | 78%   |

Legend: \(^{[18]}\)F = fluorine-18; \(^{[68]}\)Ga = gallium-68; Bi = bicentric; CUP = cancer of unknown primary; DOTA = dodecane tetraacetic acid; FAPI = fibroblast activation protein inhibitor; FDG = fluorodeoxyglucose; male\% = male percentage; Mo = monocentric; Mu = multicentric; NETs = neuroendocrine tumors; P = prospective; PET = positron emission tomography; R = retrospective.
## Table 2. Technical aspects of the included studies.

| Authors            | PET Hybrid Modality and Tomograph | Time between $^{18}$F-FDG and Radiolabeled FAPI PET | Mean $^{18}$F-FDG Injected Activity | Time between $^{18}$F-FDG injection and PET Acquisition | Mean Radiolabeled FAPI Injected Activity | Time between Radiolabeled FAPI Injection and PET Acquisition | PET Image Analysis | Reference Standard |
|--------------------|----------------------------------|-----------------------------------------------------|-------------------------------------|----------------------------------------------------------|-----------------------------------------|----------------------------------------------------------|-------------------|------------------|
| Ballal et al. [10] | GE Discovery 710 PET/CT          | within one week                                      | 271 MBq                             | 1 h                                                      | 144.3 MBq                                 | 1 h                                                      | Q and SQ Composite | Composite         |
| Chen et al. [11]   | GE Discovery MI PET/CT           | within one week                                      | 3.7 MBq/kg                          | 1 h                                                      | 1.8–2.2 MBq/kg                            | 1 h                                                      | Q and SQ Histology |                |
| Chen et al. [12]   | GE Discovery MI PET/CT           | within one week                                      | 3.7 MBq/kg                          | 1 h                                                      | 1.8–2.2 MBq/kg                            | 1 h                                                      | Q and SQ Composite |                |
| Dendl et al. [13]  | Siemens Biograph mCT PET/CT      | 1–89 days                                           | 304 MBq                             | 1 h                                                      | 185 MBq                                   | 1 h                                                      | Q and SQ Composite |                |
| Elboga et al. [14] | GE Discovery IQ PET/CT           | within one week                                      | 3.5–5.5 MBq/kg                      | 1 h                                                      | 2 MBq/kg                                  | 1 h                                                      | Q and SQ Composite |                |
| Giesel et al. [15] | Siemens Biograph mCT or GE IQ PET/CT | 1–89 days                        | 316 MBq                             | 1 h                                                      | 185 MBq                                   | 1 h                                                      | Q and SQ Composite |                |
| Guo et al. [16]    | GE Discovery MI PET/CT           | within one week                                      | 3.7 MBq/kg                          | 1 h                                                      | 148–259 MBq                               | 1 h                                                      | Q and SQ Composite |                |
| Jiang et al. [17]  | United Imaging uMR/i10 TOF PET/MRI | NR                                          | NR                                  | 1 h                                                      | 111–185 MBq                               | 1 h                                                      | Q and SQ Histology |                |
| Kessler et al. [18] | Siemens Biograph mMR PET/MRI; Siemens Biograph mCT, Philips Ingenuity TF or United Imaging uMI510 PET/MRI | within four weeks | 214 MBq                             | 1 h                                                      | 144 MBq                                   | 10 min                                                   | Q and SQ Histology |                |
| Komek et al. [19]  | GE Discovery IQ PET/CT           | within one week                                      | 3.5–5.5 MBq/kg                      | 1 h                                                      | 2 MBq/kg                                  | 1 h                                                      | Q and SQ Composite |                |
| Kreppel et al. [20] | Siemens Biograph 2, Philips Gemini GXL, or GE Discovery STE PET/CT | NR | 267 MBq | 74 min | 184 MBq | 79 min | Q and SQ Histology |
| Kuten et al. [21]  | GE Discovery MI PET/CT           | 1–23 days                                           | 3.7 MBq/kg                          | 1 h                                                      | 1.8–2.2 MBq/kg                            | 1 h                                                      | Q and SQ Composite |                |
| Lan et al. [22]    | United Imaging uMI780 PET/CT     | within three days                                    | 3.7 MBq/kg                          | 45–60 min                                                | 1.85 MBq/kg                               | 1 h                                                      | Q and SQ Composite |                |
| Linz et al. [23]   | Siemens Biograph mCT PET/CT      | 2–16 days                                           | 269 MBq                             | 1 h                                                      | 119 MBq                                   | 1 h                                                      | Q and SQ Histology |                |
| Pang et al. [24]   | GE Discovery MI PET/CT           | within one week                                      | 3.7 MBq/kg                          | 1 h                                                      | 1.8–2.2 MBq/kg                            | 1 h                                                      | Q and SQ Histology |                |
| Qin et al. [25]    | GE SIGNA PET/MRI; GE Discovery VCT PET/CT | within one week | 3.7–5.5 MBq/kg | 1 h | 1.85–3.7 MBq/kg | 30–60 min | Q and SQ Composite |
| Qin et al. [26]    | GE SIGNA PET/MRI; GE Discovery VCT PET/CT | within one week | 3.7–5.4 MBq/kg | 1 h | 1.85–3.7 MBq/kg | 30–60 min | Q and SQ Composite |
| Qin et al. [27]    | GE SIGNA PET/MRI; GE Discovery VCT PET/CT | within one week | NR | NR | 1.85–3.7 MBq/kg | 20–60 min | Q and SQ Composite |
| Sahin et al. [28]  | GE Discovery IQ PET/CT           | at least two weeks                                   | 5 MBq/kg                            | 1 h                                                      | 2–3 MBq/kg                                 | 45 min                                                   | Q and SQ Composite |                |
### Table 2. Cont.

| Authors            | PET Hybrid Modality and Tomograph | Time between \[^{18}\text{F}^{18}\text{F}-\text{FDG}\] and Radiolabeled FAPI PET | Mean \[^{18}\text{F}^{18}\text{F}-\text{FDG}\] Injected Activity | Time between \[^{18}\text{F}^{18}\text{F}-\text{FDG}\] injection and PET Acquisition | Mean Radiolabeled FAPI Injected Activity | Time between Radiolabeled FAPI Injection and PET Acquisition | PET Image Analysis | Reference Standard |
|--------------------|----------------------------------|---------------------------------|-----------------|----------------|-----------------|-------------------------------|-------------------|-------------------|
| Serfling et al. [29] | Siemens Biograph mCT PET/CT within one week | 292 MBq | 1 h | 145 MBq | 1 h | Q and SQ Histology |
| Shi et al. [30]     | Siemens Healthcare PoleStar m660 PET/CT within three days | 3.7 MBq/kg | 60-90 min | 3.59 MBq/kg | 40-50 min | Q and SQ Composite |
| Wang et al. [31]    | Siemens Biograph mCT PET/CT NR NR NR | 173.5–256.8 MBq | 60–90 min | Q and SQ Composite |
| Wang et al. [32]    | Siemens Biograph mCT PET/CT within one day | NR | NR | 185 MBq | 1 h | Q and SQ Composite |
| Zhao et al. [33]    | GE Discovery MI PET/CT within one week | 3.7-5.5 MBq/kg | 1 h | 1.8-2.2 MBq/kg | 1 h | Q and SQ Composite |
| Zhao et al. [34]    | GE Discovery MI PET/CT within one week | 3.7 MBq/kg | 1 h | 1.8-2.2 MBq/kg | 1 h | Q and SQ Composite |
| Zhao et al. [35]    | GE Discovery MI PET/CT NR | 3.7 MBq/kg | 40 min | 1.8-2.2 MBq/kg | 40 min | Q and SQ Composite |

Legend: \[^{18}\text{F}^{18}\text{F}\] = fluorine-18; Composite = histology + imaging/clinical/laboratory follow-up; CT = computed tomography; FAPI = fibroblast activation protein inhibitor; FDG = fluorodeoxyglucose; h = hour; kg = kilograms; MBq = megabecquerel; min = minutes; MRI = magnetic resonance imaging; NR = not reported; PET = positron emission Tomography; Q = qualitative; SQ = semiquantitative.

### Table 3. Main results of the included studies about the comparison among \[^{18}\text{F}^{18}\text{F}-\text{FDG}\] and FAPI radiotracers.

| Authors         | Cancer Evaluated | Significant Higher Uptake of Radiolabeled FAPI Compared to \[^{18}\text{F}^{18}\text{F}-\text{FDG}\] | Significant Higher TBR of Radiolabeled FAPI Compared to \[^{18}\text{F}^{18}\text{F}-\text{FDG}\] | Comparison in the Detection of Primary Tumors | Comparison in the Detection of Metastases |
|-----------------|------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------|----------------------------------|
| Ballal et al. [10] | Various cancers only for brain metastases only for brain metastases NR NR |
| Chen et al. [11]  | Various cancers yes yes FAPI > FDG FAPI > FDG |
| Chen et al. [12]  | Various cancers yes yes FAPI > FDG FAPI > FDG |
| Dendl et al. [13] | Gynecological cancers no only for distant metastases NR NR |
| Elboga et al. [14] | Breast cancer yes NR FAPI > FDG FAPI > FDG |
| Giesel et al. [15] | Various cancers no only for liver and bone metastases NR NR |
| Guo et al. [16]   | Liver cancer yes yes FAPI > FDG FAPI > FDG |
| Jiang et al. [17] | Gastric cancer no yes FAPI > FDG FAPI = FDG |
| Kessler et al. [18] | Sarcoma no yes FAPI = FDG FAPI = FDG |
| Komet et al. [19] | Breast cancer yes yes FAPI > FDG FAPI > FDG |
| Kreppel et al. [20] | Liver metastases of NETs yes NR FAPI > FDG FAPI > FDG |
| Kuten et al. [21] | Gastric cancer no yes FAPI > FDG FAPI > FDG |
| Lan et al. [22]   | Various cancers yes no FAPI > FDG FAPI > FDG |
| Linz et al. [23]  | Oral cancer no NR FAPI = FDG FAPI = FDG |
| Pang et al. [24]  | Gastrointestinal cancers yes NR FAPI > FDG FAPI > FDG |
| Qin et al. [25]   | Gastric cancer yes yes FAPI > FDG FAPI > FDG |
| Qin et al. [26]   | Nasopharyngeal cancer no NR FAPI = FDG FAPI = FDG |
| Qin et al. [27]   | Bone metastases or bone and joint lesions no NR NR FAPI > FDG |
| Sahin et al. [28] | Liver metastases of gastrointestinal cancers no yes NR FAPI > FDG |
Table 3. Cont.

| Authors          | Cancer Evaluated                          | Significant Higher Uptake of Radiolabeled FAPI Compared to $[^{18}F]F$-FDG | Significant Higher TBR of Radiolabeled FAPI Compared to $[^{18}F]F$-FDG | Comparison in the Detection of Primary Tumors | Comparison in the Detection of Metastases |
|------------------|--------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------|-------------------------------------------|
| Serfling et al. [29] | Suspicious tonsillary tumor or CUP         | no                                                                       | yes                                                                      | FAPI = FDG                                | FAPI < FDG                                |
| Shi et al. [30]   | Liver cancer                               | yes                                                                      | yes                                                                      | FAPI > FDG                                | FAPI > FDG                                |
| Wang et al. [31]  | Various cancers                            | no                                                                       | yes                                                                      | FAPI = FDG                                | FAPI > FDG                                |
| Wang et al. [32]  | Liver cancer                               | no                                                                       | yes                                                                      | FAPI > FDG                                | FAPI > FDG                                |
| Zhao et al. [33]  | Esophageal cancer                          | yes                                                                      | NR                                                                       | NR                                        | NR                                        |
| Zhao et al. [34]  | Peritoneal carcinomatosis                   | yes                                                                      | NR                                                                       | NR                                        | FAPI > FDG                                |
| Zhao et al. [35]  | Nasopharyngeal cancer                      | yes                                                                      | NR                                                                       | NR                                        | FAPI > FDG                                |

Legend: $[^{18}F]F$ = fluorine-18; CT = computed tomography; FAPI = fibroblast activation protein inhibitor; FDG = fluorodeoxyglucose; NR = not reported; PET = positron emission tomography; TBR = tumor-to-background ratio.

Figure 2. Quality assessment of the included studies according to QUADAS-2 tool.
2.2. Qualitative Synthesis (Systematic Review)

2.2.1. Basic Study and Patient Characteristics

Through the comprehensive computer literature search, 26 full-text articles including data on the head-to-head comparison of radiolabeled FAPI and [18F]F-FDG in cancer patients were selected (Table 1) [10–35]. All the selected articles were published in the last two years. Countries from Asia, Europe, North America and Africa were represented; the most frequent country was China followed by Germany and Turkey. About the type of study, 88% of the studies were monocentric, 12% were multicentric, 54% were retrospective and 46% were prospective. Different types of tumors were evaluated in the selected studies. The number of patients performing PET with radiolabeled FAPI and [18F]F-FDG ranged from 8 to 123. The median age of the patients included ranged from 44 to 70 years; the male percentage was highly variable from 0% to 96%.

2.2.2. Technical Aspects

Heterogeneous technical aspects among the included studies were found (Table 2). The most frequent FAPI radiotracer used was [68Ga]Ga-DOTA-FAPI-04. The hybrid imaging modality was PET/CT in most of the studies; PET/MRI was also performed in 23% of included studies. The time between [18F]F-FDG PET and radiolabeled FAPI PET ranged from one day to 89 days, even if the most frequent time range was within one week. The radiopharmaceutical injected activity largely varied among the included studies. Notably, fasting was requested only before [18F]F-FDG injection, but not before radiolabeled FAPI injection. The most frequent time from the radiopharmaceutical injection to PET image acquisition was one hour for both [18F]F-FDG and FAPI radiotracers. The PET image analysis was performed by using qualitative (visual) analysis and additional semi-quantitative analysis through the calculation of the maximal standardized uptake values (SUVmax) in all the studies. For qualitative analysis an area of increased radiopharmaceutical uptake was considered abnormal at [18F]F-FDG PET and radiolabeled FAPI PET if this uptake was higher than the background region, excluding sites of physiological uptake.

2.2.3. Radiotracer Biodistribution and Main Outcome Measures

Regarding the normal tissue biodistribution of radiolabeled FAPI in comparison to [18F]F-FDG, all the included studies showed a lower radiolabeled FAPI uptake in the normal brain, liver, and oral mucosa, compared to [18F]F-FDG [10–35].

The main outcome measures about the head-to-head comparison among [18F]F-FDG and FAPI radiotracers are listed in Table 3 and include comparison of radiopharmaceutical uptake and tumor-to-background uptake ratio (TBR) in tumor lesions, and comparison in the detection of primary tumor lesions and/or metastases.

About the comparison of the uptake of [18F]F-FDG and FAPI radiotracers in tumor lesions, there are discrepant findings among the included articles. A significantly higher uptake of radiolabeled FAPI, compared to [18F]F-FDG, was reported only in some articles and only for some types of tumors, most frequently in gastrointestinal tumors, liver tumors and breast cancer. Conversely, when investigated, most of the included articles clearly demonstrated a significant higher TBR for FAPI radiotracers, compared to [18F]F-FDG.

Overall, taking into account the radiotracer uptake and TBR values, compared to [18F]F-FDG PET, an equal or higher detection of primary tumors and/or metastatic lesions was usually demonstrated by using radiolabeled FAPI PET [10–35]. In particular, the cancer entities with better detection rate of tumor lesions by using radiolabeled FAPI PET compared to [18F]F-FDG PET were gastrointestinal tumors, liver tumors, breast cancer and nasopharyngeal carcinoma.

3. Discussion

Compared to the previous systematic reviews on FAPI imaging [8,36,37], our systematic review was focused on the head-to-head diagnostic comparison on [18F]F-FDG PET and radiolabeled FAPI PET in oncology, and therefore, only studies or subsets of studies
performing both these imaging methods in cancer patients were selected. We believe that the head-to-head comparison should be preferred, compared to indirect comparison, to obtain more solid evidence.

Overall, we found several advantages of radiolabeled FAPI PET, compared to $^{18}$F-FDG in oncology. First of all, about the patient preparation, compared to $^{18}$F-FDG, radiolabeled FAPI PET, does not require fasting or any dietary preparation, as glucose metabolic pathways are not involved; thus, a higher patient compliance is expected, compared to $^{18}$F-FDG, as radiolabeled FAPI PET is feasible even in patients with high serum glucose levels (e.g., diabetic patients).

Most of the FAPI radiotracers included in this systematic review were labeled with $^{68}$Ga obtained from a $^{68}$Ge/$^{68}$Ga generator; thus, the radiotracer can be produced on site also in small PET centers without an on-site cyclotron. On the other hand, the $^{68}$Ga activity obtained from a generator may be limited, taking into account batch size and short radionuclide half-life. Furthermore, the price of $^{68}$Ge/$^{68}$Ga generators should be considered. To overcome these drawbacks, FAPI radiolabeling with the longer-lived radionuclide $^{18}$F was recently investigated [38]. Moreover, aside from the reduced availability of $^{68}$Ge/$^{68}$Ga generators, we would like to underline that FAPI radiotracers labeled with $^{68}$Ga, which are the most used FAPI radiopharmaceuticals, are affected by a lower resolution for PET imaging with respect to FAPI radiotracers labeled with $^{18}$F, due to the high positron energy of $^{68}$Ga, compared to $^{18}$F [38].

About the normal tissue biodistribution of radiolabeled FAPI in comparison to $^{18}$F-FDG, all the included studies showed a lower radiolabeled FAPI uptake in the normal brain, liver, and oral mucosa, compared to $^{18}$F-FDG. Therefore, this is the rationale for the better detection of primary or metastatic lesions in these organs [10–35]. As radiolabeled FAPI seems to present lower background activity, compared to $^{18}$F-FDG, considering the equal or higher uptake in tumoral lesions, this may finally result in a sharper contrast [10–35]. Overall, taking into account radiotracer uptake and TBR values, compared to $^{18}$F-FDG PET, an equal or higher detection of primary tumors and/or metastatic lesions was usually demonstrated by using radiolabeled FAPI PET [10–35]. In particular, the cancer entities with better detection rate of tumor lesions by using radiolabeled FAPI PET, compared to $^{18}$F-FDG PET, were gastrointestinal tumors, liver tumors, breast cancer and nasopharyngeal carcinoma.

Furthermore, compared to $^{18}$F-FDG, using FAPI radiotracers, a theragnostic approach (e.g., diagnosis and therapy with FAPI radiotracers) seems also feasible [5]. Notably, compared to $^{18}$F-FDG, the limitation of the reduced specificity still remains with radiolabeled FAPI. As a matter of fact, $^{18}$F-FDG is known to accumulate in acute inflammation, whereas recent studies have demonstrated the increased radiolabeled FAPI uptake, due to FAP activation in chronic inflammation, causing a fibrotic reaction [8,39].

Even if the results reported by the studies included in this systematic review seem promising regarding the role of radiolabeled FAPI PET in oncology, more research studies focused on specific tumor types are still needed to clearly define the role of radiolabeled FAPI PET/CT of PET/MRI in oncology and to define whether radiolabeled FAPI may substitute $^{18}$F-FDG (e.g., in some tumor types with low glucose metabolism) or have a complementary role (e.g., possible use in patients with inconclusive findings at $^{18}$F-FDG PET).

However, the real-world scenario is still characterized by the reduced availability of radiolabeled FAPI worldwide, compared to $^{18}$F-FDG, and a small number of available research data comparing these radiotracers in specific oncological settings is currently available [39,40]. Some limitations of our systematic review should be underlined. First of all, the well-recognized clinical and methodological heterogeneity of the included studies hampered a pooled analysis (meta-analysis) and the achievement of definitive conclusions about the review question. To this regard, a meta-analysis on radiolabeled FAPI compared to $^{18}$F-FDG should be performed about specific tumor types, but unfortunately the number
of articles on specific tumor types is still limited. Furthermore, some biases of the included studies should be recognized, such as a lack of adequate reference standard in some studies and the possible publication bias, particularly in studies including a low number of patients. We have tried to limit the publication bias excluding case reports and small case series from this systematic review.

Based on current literature data, we cannot still suggest the alternative or complementary use of radiolabeled FAPI PET compared to $^{18}$F-FDG PET in oncology. Further head-to-head comparison studies among radiolabeled FAPI and $^{18}$F-FDG for specific tumor types are warranted, and in particular, cost-effectiveness analyses are strongly suggested to better define the future role of radiolabeled FAPI PET in oncology, compared to $^{18}$F-FDG PET.

4. Materials and Methods

The reporting of this systematic review conforms to the updated “Preferred Reporting Items for a Systematic Review and Meta-Analysis” (PRISMA) statement, a reporting guidance to identify, select, appraise, and synthesize studies in systematic reviews [41].

4.1. Search Strategy

Two authors (G.T. and B.M.) independently performed a comprehensive computer literature search of PubMed/MEDLINE and Cochrane library databases to find relevant articles comparing radiolabeled FAPI and $^{18}$F-FDG as PET radiotracers in oncology.

A search algorithm based on a combination of these terms was used: ((FDG) OR (fluorodeoxyglucose)) AND ((FAPI) OR (FAP) OR (fibroblast activation protein)). No beginning date limit was used. The search was updated until 28 August 2021. No language restriction was used. To expand the search, references of the retrieved articles were also screened for additional studies.

4.2. Study Selection

Studies or subsets of studies comparing radiolabeled FAPI and $^{18}$F-FDG as PET radiotracers in oncology were eligible for inclusion in the systematic review. The exclusion criteria were (a) articles not within the field of interest of this review, including studies not comparing these radiopharmaceuticals or those comparing them, but in other field than in oncology; (b) review articles, editorials, letters, comments, conference proceedings related to the review question; and (c) case reports or small case series related to the review question (<8 patients).

Two researchers (G.T. and B.M.) independently reviewed the titles and abstracts of the retrieved articles, applying the inclusion and exclusion criteria mentioned above. Articles were rejected if they were clearly ineligible. The same two researchers then independently reviewed the full-text version of the remaining articles to assess their eligibility for inclusion. Disagreements were resolved in an online consensus meeting involving all the co-authors.

4.3. Data Extraction

For each included study, information was collected by two authors independently (G.T. and B.M.) concerning basic study (authors, year of publication, country of origin, study design), patient characteristics (type or cancer evaluated, number of patients who underwent PET with both radiotracers, mean/median age, sex ratio), technical aspects (type of radiotracers, PET hybrid imaging modality and tomographs, time between PET with radiolabeled FAPI and $^{18}$F-FDG, radiotracer injected activity, time interval between radiotracer injection and image acquisition, image analysis and reference standard). Furthermore, main findings of the included studies about the comparison among $^{18}$F-FDG and FAPI radiotracers were extracted. In particular, the results on the comparison of radiopharmaceutical uptake, tumor-to-background uptake ratio (TBR) in tumor lesions, and detection of primary tumor lesions and/or metastases were extracted from the original studies.
4.4. Quality Assessment

The overall quality of the studies included in the systematic review was critically appraised by two authors (G.T. and B.M.) based on the revised “Quality Assessment of Diagnostic Accuracy Studies” tool (QUADAS-2) [42].

4.5. Statistical Analysis

Due to the significant methodological and clinical heterogeneity (considering the different types of tumors evaluated) a statistical analysis was not performed to avoid additional statistical heterogeneity [40,43,44].

5. Conclusions

Literature data about the comparison of \(^{18}\text{F}\)-FDG and radiolabeled FAPI as PET radiotracers in oncology are rapidly increasing. Overall, taking into account radiotracer uptake and TBR values, compared to \(^{18}\text{F}\)-FDG PET, an equal or higher detection of primary tumors and/or metastatic lesions was usually demonstrated by using radiolabeled FAPI PET. In particular, the cancer entities with better detection rate of tumor lesions by using radiolabeled FAPI PET compared to \(^{18}\text{F}\)-FDG PET were gastrointestinal tumors, liver tumors, breast cancer and nasopharyngeal carcinoma. Further comparison studies are inevitably needed to better evaluate the best field of application of each PET radiotracer.

Author Contributions: Conceptualization, G.T. and R.S.; methodology, G.T. and R.S.; formal analysis, G.T.; data curation, all the co-authors: H.R., Z.K., K.A. and R.S.; writing—original draft preparation, G.T.; writing—review and editing, R.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable (review article).

Informed Consent Statement: Not applicable (review article).

Data Availability Statement: Data used in this review article were extracted from scientific articles listed in PubMed/MEDLINE and Cochrane Library databases.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Vaz, S.C.; Oliveira, F.; Herrmann, K.; Veit-Haibach, P. Nuclear medicine and molecular imaging advances in the 21st century. Br. J. Radiol. 2020, 93, 20200095. [CrossRef] [PubMed]

2. Treglia, G.; Sadeghi, R.; Del Sole, A.; Giovanella, L. Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: An evidence-based review. Clin. Transl. Oncol. 2014, 16, 770–775. [CrossRef] [PubMed]

3. Brouwers, A.H.; Glaudemans, A.W.; De Vries, E.F. PET beyond \(^{18}\text{F}\)-FDG: Second generation PET tracers in clinical oncology. Q. J. Nucl. Med. Mol. Imaging 2015, 59, 1–3.

4. De Ruyscher, D.; Haustermans, K.; Thorwarth, D. FDG and Beyond. Recent Results Cancer Res. 2016, 198, 163–173. [CrossRef]

5. Lindner, T.; Loktev, A.; Altmann, A.; Giesel, F.; Kratochwil, C.; Debus, J.; Jäger, D.; Mier, W.; Haberkorn, U. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J. Nucl. Med. 2018, 59, 1415–1422. [CrossRef] [PubMed]

6. Loktev, A.; Lindner, T.; Mier, W.; Debus, J.; Altmann, A.; Jäger, D.; Giesel, F.; Kratochwil, C.; Barthe, P.; Roumestand, C.; et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J. Nucl. Med. 2018, 59, 1423–1429. [CrossRef]

7. Hamson, E.J.; Keane, F.M.; Tholen, S.; Schilling, O.; Gorrell, M.D. Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy. Proteom. Clin. Appl. 2014, 8, 454–463. [CrossRef]

8. Windisch, P.; Zwahlen, D.R.; Giesel, F.L.; Scholz, E.; Lugenihtel, P.; Debus, J.; Haberkorn, U.; Adeberg, S. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: Systematic review. EJNMRI Res. 2021, 11, 1–12. [CrossRef]

9. Dendl, K.; Schlittenhardt, J.; Staudinger, F.; Kratochwil, C.; Altmann, A.; Haberkorn, U.; Giesel, F.L. The Role of Fibroblast Activation Protein Ligands in Oncologic PET Imaging. PET Clin. 2021, 16, 341–351. [CrossRef]

10. Ballal, S.; Yadav, M.P.; Moon, E.S.; Kramer, V.S.; Roesch, F.; Kumari, S.; Tripathi, M.; ArunRaj, S.T.; Sarswat, S.; Bal, C. Biodistribution, pharmacokinetics, dosimetry of \(^{68}\text{Ga}\)Ga-DOTA.SA.FAPI, and the head-to-head comparison with \(^{18}\text{F}\)-FDG PET/CT in patients with various cancers. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 1915–1931. [CrossRef]
11. Chen, H.; Pang, Y.; Wu, J.; Zhao, L.; Hao, B.; Wu, J.; Wei, J.; Wu, S.; Zhao, L.; Luo, Z.; et al. Comparison of \(^{68}\text{Ga}\)-DOTA-FAPI-04 and \(^{18}\text{F}\)-FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 1820–1832. [CrossRef] [PubMed]

12. Chen, H.; Zhao, L.; Ruan, D.; Pang, Y.; Hao, B.; Dai, Y.; Wu, X.; Guo, W.; Fan, C.; Wu, J.; et al. Usefulness of \(^{68}\text{Ga}\)-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive \(^{18}\text{F}\)-FDG PET/CT findings. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 73–86. [CrossRef] [PubMed]

13. Dendl, K.; Koerber, S.A.; Finck, R.; Mokoala, K.M.G.; Staudinger, F.; Schillings, L.; Heger, U.; Röhrich, M.; Kratochwil, C.; Sathekege, M.; et al. \(^{68}\text{Ga}\)-FAPI-PET/CT in patients with various gynecological malignancies. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 4089–4100. [CrossRef] [PubMed]

14. Elboga, U.; Sahin, E.; Kus, T.; Cayirli, Y.B.; Aktas, G.; Uzun, E.; Cinkir, H.Y.; Teker, F.; Sever, O.N.; Aytekin, A.; et al. Superiority of \(^{68}\text{Ga}\)-FAPI PET/CT scan in detecting additional lesions compared to \(^{18}\text{F}\)-FDG PET/CT scan in breast cancer. Ann. Nucl. Med. 2021, 1–11. [CrossRef]

15. Giesel, F.L.; Kratochwil, C.; Schlittenhardt, J.; Dendl, K.; Eiber, M.; Staudinger, F.; Kessler, L.; Fendler, W.P.; Lindner, T.; Koerber, S.A.; et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of \(^{68}\text{Ga}\)-FAPI and \(^{18}\text{F}\)-FDG PET/CT in cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2021, 1–9. [CrossRef]

16. Guo, W.; Pang, Y.; Yao, L.; Zhao, L.; Fan, C.; Ke, J.; Guo, P.; Hao, B.; Fu, H.; Xie, C.; et al. Imaging fibroblast activation protein in liver cancer: A single-center post hoc retrospective analysis to compare \(^{68}\text{Ga}\)-FAPI PET/CT versus MRI and \(^{18}\text{F}\)-FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 1604–1617. [CrossRef]

17. Jiang, D.; Chen, X.; You, Z.; Wang, H.; Zhang, X.; Li, X.; Ren, S.; Huang, Q.; Hua, F.; Guan, Y.; et al. Comparison of \(^{68}\text{Ga}\)-FAPI-04 and \(^{18}\text{F}\)-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: A bicentric retrospective study. Eur. J. Nucl. Med. Mol. Imaging 2021. [CrossRef]

18. Kessler, L.; Ferdinandus, J.; Hirmas, N.; Bauer, S.; Dirkson, U.; Zarrad, F.; Nader, M.; Chodyla, M.-K.; Milosevic, A.; Umutlu, L.; et al. \(^{68}\text{Ga}\)-FAPI PET scan in disease imaging in sarcoma: Data from the FAPI-PET prospective observational trial. J. Nucl. Med. 2021. [CrossRef]

19. Kömek, H.; Can, C.; Güzel, Y.; Oruç, Z.; Gündoğan, C.; Yıldırım, Ö.A.; Kaplan, I.; Erdur, E.; Yıldırım, M.; Çakabay, B. \(^{68}\text{Ga}\)-FAPI-04 PET/CT, a new step in breast cancer imaging: A comparative pilot study with the \(^{18}\text{F}\)-FDG PET/CT. Ann. Nucl. Med. 2021, 35, 744–752. [CrossRef]

20. Kreppel, B.; Gonzalez-Carmona, M.A.; Feldmann, G.; Küppers, J.; Moon, E.S.; Marinova, M.; Bundschuh, R.A.; Kristiansen, G.; Ellis, M.; Roeckel, F.; et al. Fibroblast activation protein inhibitor (FAPI) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours. Nuklearmedizin 2021, 60, 334–354. [CrossRef]

21. Kuten, J.; Levine, C.; Shamni, O.; Pelles, S.; Wolf, I.; Lahat, G.; Mishani, E.; Even-Sapir, E. Head-to-head comparison of \(^{68}\text{Ga}\)-FAPI-04 and \(^{18}\text{F}\)-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur. J. Nucl. Med. Mol. Imaging 2021. [CrossRef]

22. Lan, L.; Liu, H.; Wang, Y.; Deng, J.; Peng, D.; Feng, Y.; Wang, Y.; Chen, Y.; Liu, L. The potential utility of \(^{68}\text{Ga}\)-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—Comparison with \(^{18}\text{F}\)-FDG. Eur. J. Nucl. Med. Mol. Imaging 2021, 1–17. [CrossRef]

23. Linz, C.; Brands, R.C.; Kertels, O.; Dierks, A.; Brumberg, J.; Gerhard-Hartmann, E.; Hartmann, S.; Schirbel, A.; Serfling, S.; Zhi, Y.; et al. Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity—Initial experience and comparison to \(^{18}\text{F}\)-FDG PET/CT and MRI. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 3951–3960. [CrossRef]

24. Pang, Y.; Zhao, L.; Luo, Z.; Hao, B.; Wu, H.; Lin, Q.; Sun, L.; Chen, H. Comparison of \(^{68}\text{Ga}\)-FAPI and \(^{18}\text{F}\)-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. Radiology 2021, 298, 393–402. [CrossRef]

25. Qin, C.; Shao, F.; Gai, Y.; Liu, Q.; Ruan, W.; Liu, F.; Hu, F.; Lan, X. \(^{68}\text{Ga}\)-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: Comparison with \(^{18}\text{F}\)-FDG PET/CT. J. Nucl. Med. 2021. [CrossRef] [PubMed]

26. Qin, C.; Liu, F.; Huang, J.; Ruan, W.; Liu, Q.; Gai, Y.; Hu, F.; Jiang, D.; Hu, Y.; Yang, K.; et al. A head-to-head comparison of \(^{68}\text{Ga}\)-DOTA-FAPI-04 and \(^{18}\text{F}\)-FDG PET/MR in patients with nasopharyngeal carcinoma: A prospective study. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 3228–3237. [CrossRef] [PubMed]

27. Qin, C.; Song, Y.; Liu, X.; Gai, Y.; Liu, Q.; Ruan, W.; Liu, F.; Hu, F.; Lan, X. Increased uptake of \(^{68}\text{Ga}\)-DOTA-FAPI-04 in bones and joints: Metastases and beyond. Eur. J. Nucl. Med. Mol. Imaging 2021, 1–12. [CrossRef]

28. Şahin, E.; Elboğa, U.; Celen, Y.Z.; Sever, Ö.N.; Çayır, Y.B.; Çimen, U. Comparison of \(^{68}\text{Ga}\)-DOTA-FAPI and \(^{18}\text{F}\)-FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer. Eur. J. Radiol. 2021, 142, 109867. [CrossRef] [PubMed]

29. Serfling, S.; Zhi, Y.; Schirbel, A.; Lindner, T.; Meyer, T.; Gerhard-Hartmann, E.; Lapa, C.; Hagen, R.; Hackenberg, S.; Buck, A.K.; et al. Improved cancer detection in Waldeyer’s tonsillar ring by \(^{68}\text{Ga}\)-FAPI PET/CT imaging. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 1178–1187. [CrossRef]

30. Shi, X.; Xing, H.; Yang, X.; Li, F.; Yao, S.; Congwei, J.; Zhao, H.; Hacker, M.; Huo, L.; Li, X. Comparison of PET imaging of activated fibroblasts and \(^{18}\text{F}\)-FDG for diagnosis of primary hepatic tumours: A prospective pilot study. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 1593–1603. [CrossRef]

31. Wang, S.; Zhou, X.; Xu, X.; Ding, J.; Liu, S.; Hou, X.; Li, N.; Zhu, H.; Yang, Z. Clinical translational evaluation of AI\(^{18}\text{F}\)-NOTA-FAPI for fibroblast activation protein–targeted tumour imaging. Eur. J. Nucl. Med. Mol. Imaging 2021, 1–13. [CrossRef]
32. Wang, H.; Zhu, W.; Ren, S.; Kong, Y.; Huang, Q.; Zhao, J.; Guan, Y.; Jia, H.; Chen, J.; Lu, L.; et al. 68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. *Front. Oncol.* 2021, 11, 693640. [CrossRef]

33. Zhao, L.; Chen, S.; Chen, S.; Pang, Y.; Dai, Y.; Hu, S.; Lin, L.; Fu, L.; Sun, L.; Wu, H.; et al. 68Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. *Radiother. Oncol.* 2021, 158, 55–61. [CrossRef] [PubMed]

34. Zhao, L.; Pang, Y.; Luo, Z.; Fu, K.; Yang, T.; Zhao, L.; Sun, L.; Wu, H.; Lin, Q.; Chen, H. Role of 68GaGa-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with 18F-FDG PET/CT. *Eur. J. Nucl. Med. Mol. Imaging* 2021, 48, 1944–1955. [CrossRef]

35. Zhao, L.; Pang, Y.; Zheng, H.; Han, C.; Gu, J.; Sun, L.; Wu, H.; Wu, S.; Lin, Q.; Chen, H. Clinical utility of 68Ga-fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. *Eur. J. Nucl. Med. Mol. Imaging* 2021, 48, 3606–3617. [CrossRef] [PubMed]

36. Windisch, P.; Zwahlen, D.R.; Koerber, S.A.; Giesel, F.L.; Debus, J.; Haberkorn, U.; Adeberg, S. Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review. *Cancers* 2020, 12, 2629. [CrossRef]

37. Sollini, M.; Kirienko, M.; Gelardi, F.; Fiz, F.; Gozzi, N.; Chiti, A. State-of-the-art of FAPI-PET imaging: A systematic review and meta-analysis. *Eur. J. Nucl. Med. Mol. Imaging* 2021, 1–19. [CrossRef]

38. Lindner, T.; Altmann, A.; Giesel, F.; Kratochwil, C.; Kleist, C.; Krämer, S.; Mier, W.; Cardinale, J.; Kauckzor, H.-U.; Jäger, D.; et al. 18F-labeled tracers targeting fibroblast activation protein. *EJNMMI Radiopharm. Chem.* 2021, 6, 1–13. [CrossRef]

39. Hicks, R.J.; Roselt, P.; Kallur, K.G.; Tothill, R.W.; Mileskey, L. FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology? *J. Nucl. Med.* 2021, 62, 296–302. [CrossRef]

40. Guglielmo, P.; Guerra, L. Radiolabeled fibroblast activation protein inhibitor (FAPI) PET in oncology: Has the time come for 18F-fluorodeoxyglucose to think to a well-deserved retirement? *Clin. Transl. Imaging* 2021, 9, 1–2. [CrossRef]

41. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Houtrron, I.; Hoffmann, T.C.; Mullrow, C.D.; Shangzeer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Syst. Rev.* 2021, 10, 1–11. [CrossRef] [PubMed]

42. Whiting, P.F.; Rutjes, A.W.S.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.; Sterne, J.A.; Bossuyt, P.M.; QUADAS-2 Group. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. *Ann. Intern. Med.* 2011, 155, 529–536. [CrossRef] [PubMed]

43. Sadeghi, R.; Treglia, G. Systematic reviews and meta-analyses of diagnostic studies: A practical guideline. *Clin. Transl. Imaging* 2017, 5, 83–87. [CrossRef]

44. Trimboli, P.; Treglia, G.; Giovanelli, L.; Bongiovanni, M. The role of systematic review and meta-analysis in modern cytopathology. *Cancer Cytopathol.* 2020, 128, 89–91. [CrossRef] [PubMed]